[go: up one dir, main page]

PE20030087A1 - Composicion farmaceutica liquida de un analogo de gaba - Google Patents

Composicion farmaceutica liquida de un analogo de gaba

Info

Publication number
PE20030087A1
PE20030087A1 PE2002000433A PE2002000433A PE20030087A1 PE 20030087 A1 PE20030087 A1 PE 20030087A1 PE 2002000433 A PE2002000433 A PE 2002000433A PE 2002000433 A PE2002000433 A PE 2002000433A PE 20030087 A1 PE20030087 A1 PE 20030087A1
Authority
PE
Peru
Prior art keywords
crashes
gaba
analogue
refers
gaba analogue
Prior art date
Application number
PE2002000433A
Other languages
English (en)
Inventor
Neema Mahesh Kulkarni
Michael Schneider
Steven Bernard Silbering
Hans Richard Meyer-Wonnay
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20030087A1 publication Critical patent/PE20030087A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION LIQUIDA QUE COMPRENDE: UN ANALOGO DE GABA TAL COMO GABAPENTINA Y PREGABALINA; DE 25% A 75% (P/V) DE UN ALCOHOL POLIHIDROXILICO C2-C6, TAL COMO GLICEROL, XILITOL, SORBITOL, MANITOL; UN CONSERVANTE ADICIONAL, UN MEJORADOR ADICIONAL DEL AROMA QUE NO CONTIENE FUNCION ALDEHIDO O CETONA; LA COMPOSICION SE CARACTERIZA POR TENER pH DE 5,5 A 7. TAMBIEN SE REFIERE A UN METODO PARA PREPARAR. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA LIQUIDA DE DOS COMPONENTES DE UN ANALOGO DE GABA QUE COMPRENDE UNA MEZCLA EN POLVO DE UN ANALOGO DE GABA Y UN ALCOHOL POLIHIDROXILICO SOLIDO; UN SEGUNDO COMPONENTE QUE COMPRENDE UNA BASE LIQUIDA. LA COMPOSICION LIQUIDA PUEDE CONTENER CONCENTRACIONES ALTAS DE UN ANALOGO DE GABA, ESTABLE, CON BAJOS NIVELES DE LACTAMA, SABOR AGRADABLE UTIL PARA EL TRATAMIENTO DE NINOS Y ANCIANOS QUE PADECEN DE EPILEPSIA, ATAQUES DE DESFALLECIMIENTOS, HIPOQUINESIA, TRAUMATISMOS CRANEALES, TRASTORNOS NEURODEGENERATIVOS, DEPRESION, MANIA
PE2002000433A 2001-05-25 2002-05-23 Composicion farmaceutica liquida de un analogo de gaba PE20030087A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
PE20030087A1 true PE20030087A1 (es) 2003-02-14

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000433A PE20030087A1 (es) 2001-05-25 2002-05-23 Composicion farmaceutica liquida de un analogo de gaba

Country Status (43)

Country Link
US (2) US20020198261A1 (es)
EP (1) EP1395242B1 (es)
JP (1) JP2004534764A (es)
KR (1) KR100582963B1 (es)
CN (1) CN100346779C (es)
AP (1) AP1815A (es)
AR (1) AR033922A1 (es)
AT (1) ATE334656T1 (es)
AU (1) AU2002258026B2 (es)
BG (1) BG108376A (es)
BR (1) BR0209973A (es)
CA (1) CA2446574C (es)
CR (1) CR7150A (es)
CY (1) CY1105147T1 (es)
CZ (1) CZ299755B6 (es)
DE (1) DE60213592T2 (es)
DK (1) DK1395242T3 (es)
DO (1) DOP2002000403A (es)
EA (1) EA008087B1 (es)
EE (1) EE200300587A (es)
EG (1) EG24078A (es)
ES (1) ES2265040T3 (es)
GE (1) GEP20053620B (es)
HR (1) HRP20030833B1 (es)
HU (1) HUP0401366A2 (es)
IL (1) IL158359A0 (es)
IS (1) IS2428B (es)
MA (1) MA27026A1 (es)
MX (1) MXPA03009392A (es)
MY (1) MY128615A (es)
NO (1) NO20035200D0 (es)
NZ (1) NZ529173A (es)
OA (1) OA12604A (es)
PA (1) PA8545901A1 (es)
PE (1) PE20030087A1 (es)
PL (1) PL366384A1 (es)
PT (1) PT1395242E (es)
RS (1) RS87203A (es)
SI (1) SI1395242T1 (es)
SK (1) SK286227B6 (es)
SV (1) SV2003001053A (es)
WO (1) WO2002094220A1 (es)
ZA (1) ZA200308393B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003250481A1 (en) * 2002-08-15 2004-03-03 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
RU2353358C2 (ru) * 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EP1680144B1 (en) * 2003-10-08 2011-10-05 Mallinckrodt LLC Methylphenidate solution and associated methods of administration and production
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
KR100870381B1 (ko) * 2004-10-14 2008-11-25 다이킨 고교 가부시키가이샤 분위기개변방법, 그리고 이에 이용되는 분무제 및 분무장치
CA2618481A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
EP1915353A2 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Isophthalsäurediamide zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2116618A1 (en) * 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CN112566625A (zh) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
CA3208954A1 (en) 2021-01-22 2022-07-28 Egis Gyogyszergyar Zrt. Topical formulation containing modified phospholipid compounds
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
EP4395758A4 (en) * 2021-08-31 2025-07-30 Avion Pharmaceuticals Llc STABLE GABAPENTIN POWDER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
CN1303991C (zh) * 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ-氨基丁酸衍生物的稳定药物制剂和其制备方法
PL365927A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
CZ20033066A3 (cs) 2004-08-18
BR0209973A (pt) 2004-04-06
SI1395242T1 (en) 2006-10-31
RS87203A (sr) 2006-10-27
GEP20053620B (en) 2005-09-26
CA2446574A1 (en) 2002-11-28
DOP2002000403A (es) 2002-11-30
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
AP1815A (en) 2008-01-04
MA27026A1 (fr) 2004-12-20
JP2004534764A (ja) 2004-11-18
PA8545901A1 (es) 2003-09-05
EP1395242A1 (en) 2004-03-10
IS6986A (is) 2003-10-09
EG24078A (en) 2008-05-11
CA2446574C (en) 2008-04-01
CN1509165A (zh) 2004-06-30
MY128615A (en) 2007-02-28
ATE334656T1 (de) 2006-08-15
US7256216B2 (en) 2007-08-14
AP2003002907A0 (en) 2003-12-31
CZ299755B6 (cs) 2008-11-12
KR20040003006A (ko) 2004-01-07
IL158359A0 (en) 2004-05-12
EP1395242B1 (en) 2006-08-02
PL366384A1 (en) 2005-01-24
BG108376A (bg) 2005-04-30
HUP0401366A2 (hu) 2004-11-29
ES2265040T3 (es) 2007-02-01
IS2428B (is) 2008-10-15
HRP20030833B1 (en) 2007-04-30
CR7150A (es) 2004-02-23
US20020198261A1 (en) 2002-12-26
DK1395242T3 (da) 2006-10-30
EA008087B1 (ru) 2007-02-27
ZA200308393B (en) 2005-04-26
EA200301152A1 (ru) 2004-04-29
SK286227B6 (sk) 2008-05-06
US20040072904A1 (en) 2004-04-15
CN100346779C (zh) 2007-11-07
HRP20030833A2 (en) 2004-08-31
DE60213592D1 (de) 2006-09-14
KR100582963B1 (ko) 2006-05-24
AU2002258026B2 (en) 2007-08-02
EE200300587A (et) 2004-02-16
NO20035200L (no) 2003-11-24
HK1062646A1 (zh) 2004-11-19
DE60213592T2 (de) 2007-08-09
SK14112003A3 (sk) 2004-08-03
CY1105147T1 (el) 2010-03-03
NZ529173A (en) 2005-07-29
SV2003001053A (es) 2003-03-18
OA12604A (en) 2006-06-08
WO2002094220A1 (en) 2002-11-28
AR033922A1 (es) 2004-01-07
NO20035200D0 (no) 2003-11-24

Similar Documents

Publication Publication Date Title
PE20030087A1 (es) Composicion farmaceutica liquida de un analogo de gaba
WO2010091649A4 (en) A composition for buccal absorption of nicotine for the purpose of smoking cessation
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
JP2004018431A (ja) 口腔用香料組成物および該香料組成物を含有する口腔組成物
US20100099771A1 (en) Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP0858329A1 (fr) Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
BRPI0009299B8 (pt) formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis.
KR970702033A (ko) 택산 계열 유도체-기본 약학 조성물(taxane class derivative based pharmaceutical compositions)
JPH03128318A (ja) 筋力持続剤,滋養強壮剤,輸液用剤,栄養補給剤,疲労回復剤及び乳酸生成調節剤
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
ECSP045349A (es) Formuilaciones liquidas de baja dosis de entecavir y uso
RU2706242C2 (ru) Ополаскиватели и композиции для лечения чувствительности зубов
RS50685B (sr) Koncentrovani vodeni rastvor ambroksola
MA27669A1 (fr) Formulations topiques stabilisees contenant du ketoprofene
EA200701986A1 (ru) Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
AU2012201629B2 (en) Flavor composition containing flavone glycosides
RU2008116871A (ru) Органолептически приемлемые пероральные лекарственные формы ибупрофена, способы их приготовления и применения
US6927231B2 (en) Use of creatine for the amelioration of oxidative stress
US20110245349A1 (en) Benzyl alcohol mixture for treating premature ejaculation
WO2004058137A3 (fr) Compositions pour administration orale de principes actifs necessitant un masquage du gout
JP2005041853A (ja) 特定の金属酵素を刺激する組成物
BE1026122A1 (fr) Composition pour prévenir ou réduire les effets d'une intoxication alcoolique
JP2007332046A (ja) ヘアシャンプー
JP2006328079A (ja) 特定の金属酵素を刺激する組成物

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed